Tools for Practice Outils pour la pratique


#308 Can It Stay or Must It Go? Extended Use of Intrauterine Devices


CLINICAL QUESTION
QUESTION CLINIQUE
How effective and safe are levonorgestrel and copper-T380A intrauterine devices for preventing pregnancy beyond the recommended durations of use?


BOTTOM LINE
RÉSULTAT FINAL
If it is not possible or desirable to replace a levonorgestrel 52mg or copper-T380A intrauterine device (IUD) at the end of the approved duration of use, small observational studies demonstrated similar efficacy and safety for up to two additional years, with little evidence afterwards. Guidelines suggest that with patient-informed discussion, deferral of IUD replacement for up to twelve months is reasonable.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • One systematic review:1
    • Levonorgestrel (LNG) IUD 52 mg (Mirena™): 4 cohort studies, 2089 participants:
      • Health Canada approved duration: 5 years.2
      • Years 6 & 7:
        • 0.02 pregnancies per 100 person-years (95% CI 0–0.29).
        • Expulsion and infection rates: ~0-3%.
        • Bleeding/pain leading to discontinuation 0.2 to 6.2%.
      • No data on devices with other levonorgestrel dosages.
    • Copper-T380A IUD: 2 cohort studies, 473 participants:
      • Health Canada approved duration: 10 years.3
      • Years 11 & 12:
        • No pregnancies reported (95% CI 0–0.8 pregnancies per 100 person-years).
        • Expulsion rate ~1%.
        • No infections or perforations (reported in one study).
        • Bleeding/pain leading to discontinuation 1-5%.
    • An earlier systematic review4 found similar results.
  • Limitations:
    • No randomized controlled trials were identified. Evidence presented is from relatively small observational studies.
    • Most studies were in parous participants.
Context
  • Statements from the Society of Obstetricians and Gynecologists of Canada (SOGC) and the American College of Obstetricians and Gynecologists (ACOG) are consistent with these findings.5,6
    • SOGC: “Intrauterine contraception (IUC) may be safely continued beyond its approved duration of use.” Removal or replacement may be deferred for up to 12 months.
    • ACOG: “Data indicate that the copper IUD, [and] the LNG-20 IUD… are all effective beyond their FDA-approved durations of use.”
  • Average annual rates during first five (LNG) or ten (copper-T380A) years of use7:
    • Pregnancy: ~0.1% (LNG), ~0.4% (copper-T380A).
    • Expulsion and infection rates: ~0.06-1% (LNG), ~0.02-1.5% (copper-T380A).
    • Discontinuation due to bleeding or pain: ~7% (LNG), ~3% (copper-T380A).
  • IUD cost is ~$350 (LNG 52mg) or ~$78 (copper-T380A).8


Jason Price February 14, 2022

some replacement deferral is reasonable

Thomas Nel February 14, 2022

interesting

Thomas Nel February 14, 2022

informative

Gilbert Bretecher February 24, 2022

iud’s are effective beyond their expiatory date.


Latest Tools for Practice
Derniers outils pour la pratique

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles

#361 Preventing RSV Infections in Infants

How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Ingrid Baragar MD
  • Jessica Kirkwood MD CCFP (AM)
  • Allison Paige MD CCFP
  • Jennifer Potter MD CCFP

1. Ti AJ, Roe AH, Whitehouse KC, et al. Am J Ob Gyn. 2020; 223(1):24-35.

2. Mirena™ [product monograph]. Mississauga (ON): Bayer Inc.; November 24, 2020. Available from https://pdf.hres.ca/dpd_pm/00059006.PDF Accessed June 18, 2021.

3. Mona Lisa 10™ [product insert]. Kirkland (QC): Besins Healthcare Canada; July 3, 2015. Available from https://www.dufortlavigne.com/system/files/fiches/techniques_en/PUN025351.pdf Accessed June 18, 2021.

4. Wu JP, Pickle S. Contraception. 2014; 89:495-503.

5. Black A, Costescu D, Guibert E, et al. SOGC Sexual Health and Reproductive Equity (SHARE) Committee Statement. April 18. 2020. Available at https://sogc.org/common/Uploaded%20files/2020-04%20Contraception%20Consensus%20-%20Final%20Submitted.pdf Accessed September 23, 2021.

6. Committee on Practice Bulletins-Gynecology. Obstet Gynecol. 2017; 130(5):e251-e269. Available from https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2017/11/long-acting-reversible-contraception-implants-and-intrauterine-devices Accessed September 23, 2021.

7. Rowe P, Farley T, Peregoudov A, et al. Contraception. 2016; 93:498-506.

8. Price Comparison of Commonly Prescribed Medications in Manitoba 2021. Available at https://medsconference.files.wordpress.com/2021/01/price-comparison-commonly-rx-drugs-mb-2020-jan-28-2021.pdf Accessed June 18, 2021.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.